RSA Viewpoints
RSA Viewpoint | Why we should stop talking about Diversity & Inclusion Initiatives
We know the life sciences sector desperately needs diversity across the board. The industry is facing a demographic time bomb: many of the current...
Launching your first medical product in Europe? How not to fail at the first step
So, you have your first product close to launch or are even on the market in the U.S. You’re planning to take it to...
AMRC | HR Benchmarking Report
In May 2018, the Association of Medical Research Charities (AMRC) circulated a survey of 50 questions to member charity CEOs and formal representatives. The...
Brexit’s Uncertainty Principle
While the minutiae of the possible upcoming permutations for drug supply depending on various Brexit outcomes have been written about elsewhere, less thought has been...
Bringing fresh talent into the Alzheimer’s space
It’s more than 15 years since the pharmaceutical industry succeeded in launching a new drug to treat Alzheimer’s disease. Since then, over 99% of...
Pharmafile | The Value of Measuring Board Performance
Nick Stephens of The RSA Group discusses the importance of stopping to quantify the effectiveness of board members within life sciences, and offers guidance...
Employers Using Social Media More and More to Screen Candidates
According to a new CareerBuilder survey, 70 percent of employers use social media to screen candidates before hiring, up from 60 percent just two...
Recruitment International | Becoming GDPR-ready
Nick Stephens, executive chairman at The RSA Group, discusses how the company became GDPR- ready before May 2018 and reveals the role AI is...
Executive Interims: A creative talent solution for medtech
After attending two recent medtech industry meetings, I was struck by the scale of the two opposing forces that the sector is currently experiencing....
Solving the Life Sciences talent puzzle in Asia
Living and working in the Asia-Pacific region for the past 7 years has given me a close-up view of the fast growth of its...
Who guards the Guards in life science companies?
This isn’t a new question; it’s been asked by every civilisation, from the Greeks on holding people in power to account, and the Romans...
Outlook: Medtech 2030
Having travelled in Europe in the last few weeks meeting clients and candidates, I wanted to share some reflections with you linked to one...
Swiss Biotech Day 2018: Themes,trends and thoughts
Last week I attended the Swiss BioTech Annual Meeting and their 20th Anniversary. The Life Sciences industry is facing a fascinating new era, and...
Where are all the medtech medics?
For many years now there has been a clear path for medical professionals who move from education to working in the pharmaceutical industry, both...
Finding talent for late stage neuroscience drug development
At a recent OBN/One Nucleus BioTuesday focusing on neurodegenerative diseases, I heard again the extent of the challenge faced by scientists wanting to develop...
Efficient engagement with executive search
When looking for a new role, you’ll have plenty of questions for a potential new employer. Ahead of any interview, you’ll do your due...
Lateral thinking for oncology leadership
The rapid growth in immuno-oncology therapeutics is causing talent headaches for the pharma industry Patients are already benefitting from pharma’s success in developing new...
New talent needed for a new era of market access in the medtech industry
The last decade has seen the unprecedented growth of innovative and improved medical technologies. In turn, this has led to the development of a...